{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:30:10Z","timestamp":1779910210235,"version":"3.53.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sphingosine-1-phosphate (S1P) has been implicated in promoting breast cancer progression, but its role in fostering an immunosuppressive microenvironment remains largely unexplored. In our study, co-culturing CD8 T cells with S1P-treated MCF7 cells significantly reduced CD8 T cell proliferation, an effect reversed by inhibiting exosome biogenesis. S1P treatment enhanced exosome release from breast cancer cells, with increased levels of TGFBR2 detected on the exosome surface. These S1P-induced exosomes promoted CD8 T cell exhaustion. Silencing TGFBR2 in cancer cells or treating with anti-TGFBR2 antibodies mitigated CD8 T cell exhaustion thereby highlighting the pivotal role of TGFBR2. Further investigation revealed that S1P drives the production of TGFBR2-loaded exosomes by activating the S1P1 receptor and engaging the AKT-Rab27a axis to facilitate exosome release. Additionally, S1P upregulates TGFBR2 expression and stability through the S1P1-LEF1 and S1P1-CREB1-USP8 pathways respectively, thereby contributing to immune suppression. In vivo administration of exosomes derived from S1P-treated murine breast cancer cells in a breast cancer allograft model markedly promoted tumor growth and heightened CD8 T cell exhaustion, whereas exosomes from TGFBR2-silenced, S1P-treated cells exerted the reverse effect, underscoring the pivotal role of the S1P-TGFBR2 axis in modulating the tumor microenvironment. These findings suggest that targeting the S1P-TGFBR2 pathway could enhance antitumor immunity in breast cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-08523-5","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:34:25Z","timestamp":1774287265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sphingosine-1-phosphate promotes CD8 T cell exhaustion in breast cancer via exosomal transfer of TGFBR2"],"prefix":"10.1038","volume":"17","author":[{"given":"Avinandan","family":"Bhoumick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhasis","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-1822","authenticated-orcid":false,"given":"Prosenjit","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"8523_CR1","unstructured":"Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (accessed 28 Jun2025)."},{"key":"8523_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8523_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423\u201337.","journal-title":"Nat Med"},{"key":"8523_CR4","first-page":"15","volume":"56","author":"B Arneth","year":"2019","unstructured":"Arneth B. Tumor Microenvironment. Med. 2019;56:15.","journal-title":"Med"},{"key":"8523_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion. Science (80-). 2011;331:1565\u201370.","journal-title":"Science (80-)"},{"key":"8523_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"8523_CR7","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185\u2013S198.","journal-title":"Semin Cancer Biol"},{"key":"8523_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"8523_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"8523_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"8523_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science (80-). 2015;348:56\u201361.","journal-title":"Science (80-)"},{"key":"8523_CR12","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 2015;372:2006\u201317.","journal-title":"N Engl J Med"},{"key":"8523_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"8523_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"8523_CR15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"8523_CR16","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and Activity of Anti\u2013PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"8523_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"8523_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"8523_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:1\u201314.","journal-title":"Mol Cancer"},{"key":"8523_CR20","doi-asserted-by":"publisher","unstructured":"Kalluri R, LeBleu VS The biology, function, and biomedical applications of exosomes. Science (80-) 2020; 367. https:\/\/doi.org\/10.1126\/SCIENCE.AAU6977\/ASSET\/F5050DD7-9124-4A75-9FBE-2BCDF3F27CD8\/ASSETS\/GRAPHIC\/367_AAU6977_F6.JPEG.","DOI":"10.1126\/SCIENCE.AAU6977\/ASSET\/F5050DD7-9124-4A75-9FBE-2BCDF3F27CD8\/ASSETS\/GRAPHIC\/367_AAU6977_F6.JPEG"},{"key":"8523_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.smim.2017.12.003","volume":"35","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. 2018;35:69\u201379.","journal-title":"Semin Immunol"},{"key":"8523_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18:1\u201314.","journal-title":"Mol Cancer"},{"key":"8523_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414\u201327.e13.","journal-title":"Cell"},{"key":"8523_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nat. 2018;560:382\u20136.","journal-title":"Nat"},{"key":"8523_CR25","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/ijc.24249","volume":"124","author":"X Xiang","year":"2009","unstructured":"Xiang X, Poliakov A, Liu C, Liu Y, Deng Z, Bin, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124:2621\u201333.","journal-title":"Int J Cancer"},{"key":"8523_CR26","first-page":"38","volume":"2","author":"TL Whiteside","year":"2017","unstructured":"Whiteside TL. The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer. Wspolczesna Onkol. 2017;2:38\u201340.","journal-title":"Wspolczesna Onkol"},{"key":"8523_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang X, Shi H, Yuan X, Jiang P, Qian H, Xu W. Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol Cancer. 2018;17:1\u201316.","journal-title":"Mol Cancer"},{"key":"8523_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-31250-2","volume":"13","author":"F Xie","year":"2022","unstructured":"Xie F, Zhou X, Su P, Li H, Tu Y, Du J, et al. Breast cancer cell-derived extracellular vesicles promote CD8+\u2009T cell exhaustion via TGF-\u03b2 type II receptor signaling. Nat Commun. 2022;13:1\u201318.","journal-title":"Nat Commun"},{"key":"8523_CR29","doi-asserted-by":"publisher","unstructured":"Xie F, Zhou X, Li H, Su P, Liu S, Li R et al. USP8 promotes cancer progression and extracellular vesicle-mediated CD8 + T cell exhaustion by deubiquitinating the TGF -\u03b2 receptor T\u03b2RII. EMBO J 2022; 41. https:\/\/doi.org\/10.15252\/EMBJ.2021108791\/SUPPL_FILE\/EMBJ2021108791-SUP-0009-SDATAEV.ZIP.","DOI":"10.15252\/EMBJ.2021108791\/SUPPL_FILE\/EMBJ2021108791-SUP-0009-SDATAEV.ZIP"},{"key":"8523_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-019-0282-2","volume":"9","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:1\u201318.","journal-title":"Cell Biosci"},{"key":"8523_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","volume":"30","author":"M Colombo","year":"2025","unstructured":"Colombo M, Raposo G, Th\u00e9ry C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev Biol. 2025;30:255\u201389.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"8523_CR32","doi-asserted-by":"publisher","unstructured":"Th\u00e9ry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018; 7. https:\/\/doi.org\/10.1080\/20013078.2018.1535750;WGROUP:STRING:PUBLICATION.","DOI":"10.1080\/20013078.2018.1535750"},{"key":"8523_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun YA, Obeid LM. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139\u201350.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8523_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2875","volume":"10","author":"NJ Pyne","year":"2010","unstructured":"Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489\u2013503.","journal-title":"Nat Rev Cancer"},{"key":"8523_CR35","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1111\/cas.13802","volume":"109","author":"M Nagahashi","year":"2018","unstructured":"Nagahashi M, Abe M, Sakimura K, Takabe K, Wakai T. The role of sphingosine-1-phosphate in inflammation and cancer progression. Cancer Sci. 2018;109:3671\u20138.","journal-title":"Cancer Sci"},{"key":"8523_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/lrb.2012.0010","volume":"10","author":"T Aoyagi","year":"2012","unstructured":"Aoyagi T, Nagahashi M, Yamada A, Takabe K. The role of sphingosine-1-phosphate in breast cancer tumor-induced lymphangiogenesis. Lymphat Res Biol. 2012;10:97\u2013106.","journal-title":"Lymphat Res Biol"},{"key":"8523_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1042\/BST20110602","volume":"40","author":"NJ Pyne","year":"2012","unstructured":"Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans. 2012;40:94\u2013100.","journal-title":"Biochem Soc Trans"},{"key":"8523_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1124\/pr.107.07113","volume":"60","author":"K Takabe","year":"2008","unstructured":"Takabe K, Paugh SW, Milstien S, Spiegel S. \u201cInside-Out\u201d Signaling of Sphingosine-1-Phosphate: Therapeutic Targets. Pharmacol Rev. 2008;60:181\u201395.","journal-title":"Pharmacol Rev"},{"key":"8523_CR39","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/biomedicines9091121","volume":"9","author":"A Zulueta","year":"2021","unstructured":"Zulueta A, Dei Cas M, Luciano F, Mingione A, Pivari F, Righi I, et al. Spns2 transporter contributes to the accumulation of s1p in cystic fibrosis human bronchial epithelial cells. Biomedicines. 2021;9:1121.","journal-title":"Biomedicines"},{"key":"8523_CR40","doi-asserted-by":"publisher","first-page":"4806541","DOI":"10.1155\/2017\/4806541","volume":"2017","author":"NC Hait","year":"2017","unstructured":"Hait NC, Maiti A. The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer. Mediators Inflamm. 2017;2017:4806541.","journal-title":"Mediators Inflamm"},{"key":"8523_CR41","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/ijms25063354","volume":"25","author":"M Nagahashi","year":"2024","unstructured":"Nagahashi M, Miyoshi Y. Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer. Int J Mol Sci. 2024;25:3354.","journal-title":"Int J Mol Sci"},{"key":"8523_CR42","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675\u201399.","journal-title":"Cell Metab"},{"key":"8523_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/651727","volume":"2014","author":"M Nagahashi","year":"2014","unstructured":"Nagahashi M, Takabe K, Terracina KP, Soma D, Hirose Y, Kobayashi T, et al. Sphingosine-1-Phosphate Transporters as Targets for Cancer Therapy. Biomed Res Int. 2014;2014:651727.","journal-title":"Biomed Res Int"},{"key":"8523_CR44","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/sj.bjc.6603400","volume":"95","author":"RA Sabbadini","year":"2006","unstructured":"Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer. 2006;95:1131\u20135.","journal-title":"Br J Cancer"},{"key":"8523_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308131","volume":"11","author":"Y An","year":"2024","unstructured":"An Y, Zhu J, Xie Q, Feng J, Gong Y, Fan Q, et al. Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling. Adv Sci. 2024;11:2308131.","journal-title":"Adv Sci"},{"key":"8523_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/21541248.2016.1264352","volume":"9","author":"L Blanc","year":"2018","unstructured":"Blanc L, Vidal M. New insights into the function of Rab GTPases in the context of exosomal secretion. Small GTPases. 2018;9:95\u2013106.","journal-title":"Small GTPases"},{"key":"8523_CR47","doi-asserted-by":"publisher","unstructured":"Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W et al. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep 2023; 42. https:\/\/doi.org\/10.1016\/J.CELREP.2023.113224.","DOI":"10.1016\/J.CELREP.2023.113224"},{"key":"8523_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05265-y","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Li X, Wang R, Hua D, Sun C, Yu L, et al. Recruitment of LEF1 by Pontin chromatin modifier amplifies TGFBR2 transcription and activates TGF\u03b2\/SMAD signalling during gliomagenesis. Cell Death Dis. 2022;13:1\u201313.","journal-title":"Cell Death Dis"},{"key":"8523_CR49","doi-asserted-by":"publisher","unstructured":"Joshi K, Mazumdar V, Nandi BR, Radhakrishnan GK Brucella targets the host ubiquitin-specific protease, Usp8, through the effector protein, TcpB, for facilitating infection of macrophages. Infect Immun 2024; 92. https:\/\/doi.org\/10.1128\/IAI.00289-23\/SUPPL_FILE\/IAI.00289-23-S0004.DOCX.","DOI":"10.1128\/IAI.00289-23\/SUPPL_FILE\/IAI.00289-23-S0004.DOCX"},{"key":"8523_CR50","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.celrep.2019.11.036","volume":"29","author":"VA Balaji Ragunathrao","year":"2019","unstructured":"Balaji Ragunathrao VA, Anwar M, Akhter MZ, Chavez A, Mao DY, Natarajan V, et al. Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling. Cell Rep. 2019;29:3472.","journal-title":"Cell Rep"},{"key":"8523_CR51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ebiom.2018.10.005","volume":"37","author":"S Song","year":"2018","unstructured":"Song S, Min H, Niu M, Wang L, Wu Y, Zhang B, et al. S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activation. EBioMedicine. 2018;37:168\u201376.","journal-title":"EBioMedicine"},{"key":"8523_CR52","first-page":"1","volume":"10","author":"YN Liu","year":"2019","unstructured":"Liu YN, Zhang H, Zhang L, Cai TT, Huang DJ, He J, et al. Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer. Cell Death Dis. 2019;10:1\u201311.","journal-title":"Cell Death Dis"},{"key":"8523_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1369-7","volume":"38","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhi Y, Song H, Zong M, Yi J, Mao G, et al. S1PR1 promotes proliferation and inhibits apoptosis of esophageal squamous cell carcinoma through activating STAT3 pathway. J Exp Clin Cancer Res. 2019;38:1\u201315.","journal-title":"J Exp Clin Cancer Res"},{"key":"8523_CR54","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jss.2020.11.044","volume":"259","author":"T Yokota","year":"2021","unstructured":"Yokota T, Nojima H, Kuboki S, Yoshitomi H, Furukawa K, Takayashiki T, et al. Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma. J Surg Res. 2021;259:200\u201310.","journal-title":"J Surg Res"},{"key":"8523_CR55","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1016\/j.febslet.2005.08.055","volume":"579","author":"S Sarkar","year":"2005","unstructured":"Sarkar S, Maceyka M, Hait NC, Paugh SW, Sankala H, Milstien S, et al. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 2005;579:5313\u20137.","journal-title":"FEBS Lett"},{"key":"8523_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ni Y, Liang X, Lin Y, An B, He X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol. 2022;13:915094.","journal-title":"Front Immunol"},{"key":"8523_CR57","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, \u00c1lvarez-Errico D, Esteller M. The Contribution of Epigenetics to Cancer Immunotherapy. Trends Immunol. 2020;41:676\u201391.","journal-title":"Trends Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08523-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:04:19Z","timestamp":1774368259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08523-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8523"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08523-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}